Advanced

Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer.

Boman, Karolina LU ; Larsson, Anna H LU ; Segersten, U; Kuteeva, E; Johannesson, Henrik; Nodin, Björn LU ; Eberhard, Jakob LU ; Uhlén, M; Malmström, P-U and Jirström, Karin LU (2013) In British Journal of Cancer 108(11). p.2321-2328
Abstract
Background:Membranous expression of the anti-adhesive glycoprotein podocalyxin-like (PODXL) has previously been found to correlate with poor prognosis in several major cancer forms. Here we examined the prognostic impact of PODXL expression in urothelial bladder cancer.Methods:Immunohistochemical PODXL expression was examined in tissue microarrays with tumours from two independent cohorts of patients with urothelial bladder cancer: n=100 (Cohort I) and n=343 (Cohort II). The impact of PODXL expression on disease-specific survival (DSS; Cohort II), 5-year overall survival (OS; both cohorts) and 2-year progression-free survival (PFS; Cohort II) was assessed.Results:Membranous PODXL expression was significantly associated with more advanced... (More)
Background:Membranous expression of the anti-adhesive glycoprotein podocalyxin-like (PODXL) has previously been found to correlate with poor prognosis in several major cancer forms. Here we examined the prognostic impact of PODXL expression in urothelial bladder cancer.Methods:Immunohistochemical PODXL expression was examined in tissue microarrays with tumours from two independent cohorts of patients with urothelial bladder cancer: n=100 (Cohort I) and n=343 (Cohort II). The impact of PODXL expression on disease-specific survival (DSS; Cohort II), 5-year overall survival (OS; both cohorts) and 2-year progression-free survival (PFS; Cohort II) was assessed.Results:Membranous PODXL expression was significantly associated with more advanced tumour (T) stage and high-grade tumours in both cohorts, and a significantly reduced 5-year OS (unadjusted HR=2.25 in Cohort I and 3.10 in Cohort II, adjusted HR=2.05 in Cohort I and 2.18 in Cohort II) and DSS (unadjusted HR=4.36, adjusted HR=2.70). In patients with Ta and T1 tumours, membranous PODXL expression was an independent predictor of a reduced 2-year PFS (unadjusted HR=6.19, adjusted HR=4.60) and DSS (unadjusted HR=8.34, adjusted HR=7.16).Conclusion:Membranous PODXL expression is an independent risk factor for progressive disease and death in patients with urothelial bladder cancer.British Journal of Cancer advance online publication, 7 May 2013; doi:10.1038/bjc.2013.215 www.bjcancer.com. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
British Journal of Cancer
volume
108
issue
11
pages
2321 - 2328
publisher
Nature Publishing Group
external identifiers
  • wos:000320249500016
  • pmid:23652315
  • scopus:84884185522
ISSN
1532-1827
DOI
10.1038/bjc.2013.215
language
English
LU publication?
yes
id
59451232-9eb4-425f-8401-661993b0f9fa (old id 3804795)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23652315?dopt=Abstract
date added to LUP
2013-06-06 15:50:16
date last changed
2019-07-09 01:11:07
@article{59451232-9eb4-425f-8401-661993b0f9fa,
  abstract     = {Background:Membranous expression of the anti-adhesive glycoprotein podocalyxin-like (PODXL) has previously been found to correlate with poor prognosis in several major cancer forms. Here we examined the prognostic impact of PODXL expression in urothelial bladder cancer.Methods:Immunohistochemical PODXL expression was examined in tissue microarrays with tumours from two independent cohorts of patients with urothelial bladder cancer: n=100 (Cohort I) and n=343 (Cohort II). The impact of PODXL expression on disease-specific survival (DSS; Cohort II), 5-year overall survival (OS; both cohorts) and 2-year progression-free survival (PFS; Cohort II) was assessed.Results:Membranous PODXL expression was significantly associated with more advanced tumour (T) stage and high-grade tumours in both cohorts, and a significantly reduced 5-year OS (unadjusted HR=2.25 in Cohort I and 3.10 in Cohort II, adjusted HR=2.05 in Cohort I and 2.18 in Cohort II) and DSS (unadjusted HR=4.36, adjusted HR=2.70). In patients with Ta and T1 tumours, membranous PODXL expression was an independent predictor of a reduced 2-year PFS (unadjusted HR=6.19, adjusted HR=4.60) and DSS (unadjusted HR=8.34, adjusted HR=7.16).Conclusion:Membranous PODXL expression is an independent risk factor for progressive disease and death in patients with urothelial bladder cancer.British Journal of Cancer advance online publication, 7 May 2013; doi:10.1038/bjc.2013.215 www.bjcancer.com.},
  author       = {Boman, Karolina and Larsson, Anna H and Segersten, U and Kuteeva, E and Johannesson, Henrik and Nodin, Björn and Eberhard, Jakob and Uhlén, M and Malmström, P-U and Jirström, Karin},
  issn         = {1532-1827},
  language     = {eng},
  number       = {11},
  pages        = {2321--2328},
  publisher    = {Nature Publishing Group},
  series       = {British Journal of Cancer},
  title        = {Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer.},
  url          = {http://dx.doi.org/10.1038/bjc.2013.215},
  volume       = {108},
  year         = {2013},
}